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Abstract 
Zis, Athanasios P., Roger F. Haskett, A. Ariav Albala, Bernard J. Carroll: Escape from 
Dexamethasone Suppression: Possible Role of an Impaired Inhibitory Opioid Mechanism. Prog . 







Several lines of evidence indicate that the activity of the hypothalamus-pituitary- 
adrenal (HPA) axis in depression is disinhibited. 
Escape from dexamethasone suppression, although not limited to is more frequent in 
patients with endogenous depression compared to normals or patients with other psychia- 
tric diagnoses. 
Norepinephrine, serotonin and acetylcholine have been implicated in the pathophysiology 
of this neuroendocrine abnormal i ty. 
Morphine, 5 mg intravenously, suppressed cortisol secretion in healthy volunteers (n=4) 
and the majority of 32 psychiatric inpatients. 
However, patients with endogenous depression and abnormal dexamethasone suppression test 
results show early resumption (escape) of cor-&ol secretion following the initial 
suppression induced by morphine. 
It is concluded that the pathophysiology of this neuroendocrine abnormality is not limit- 
ed to classical neurotransmitter-ffPA axis interaction but that it also involves opioid 
inhibitory mechanisms. 
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Introduction 
Several lines of evidence implicate disinhibited activity of the hypothalamus-pituitary- 
adrenal (HPA) axis in the pathophysiology of depression (Sachar et al., 1973; Carroll et al., 
1976a; Carroll et al., 1976b). Considerable support for this thesis has been derlved from 
studies of the effects of dexamethasone on plasma cortisol; cortisol escape from dexametha- 
sone , albeit not limited to, is characteristically more frequent in patients with endogenous 
depresslon than in normal subjects, non-endogenous depressives or in patients with other 
psychiatric diagnoses (Carrot1 et al., 1981, Copper et al., 1983). Although several hypo- 
theses haye been suggested, the s’te and precise mechanism of this neuroendocrine dysregu- 
lation remains unclear. The purpose of this peper is to review hypotheses implicating 
classical neurotransmitter systems in this abnormality and to present data indicating the 
involvement of impaired opioid inhibitory mechanisms. In doing so we will limit our 
discussion to studies pertalning to depression; for a general discussion of the neurotrans- 
mitter regulation of the HPA axis and the pathophysiology of thissystem in Cushing’s disease 
the reader is referred elsewhere (Martin et al., 1977; Relchlin, 1981). 
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A. The Role of Classical Neurotransmitter Systems 
Catecholamines, the indoleamine serotonin and acetylcholine, alone or in combination, have 
all been implicated in the pathophysiology of depression. Since these neurotransmitters play 
an important role in neutoendocrine regulation, it is not surprising that they have been 
implicated in thisdysregulation of the HPA axis present in depression. In examining their 
role in the neuroendocrine abnormality it is important to consider that the neurotransmitter 
control of ACTH has proven to be the most difficult to study of all the anterior pituitary 
hormone systems, and that there is considerable controversy regarding the specific effects of 
the various neurotransmitters on this system. According to the model most widely accepted 
(Martin et al., 1977; Reichlin, 1581), serotonin and actylcholine stimulate the secretion of 
ACTH and cortisol whereas norepinephrine appears to exert both inhibitory (mediated by B- 
adrenoreceptors) and excitatory (mediated by a-adrenoreceptors) effects. Dopamine appears to 
play no major role in the regulation of the HPA axis. 
Norepinephrine. The evidence supporting the involvement of a noradrenergic mechanism in 
the disinhibited HPA axis activity derives from the studies of Checkley (1979) and Sachar 
(1982). Checkley (1979) reported that the cortisol response to methamphetamine is attenuated 
in patients with endogenous depression compared to recovered patients, non-endogenous depres- 
sives, or patients with other psychhatric di,agnoses. Sachar (1982) reports that the adminis- 
tration of dextroaphetamine inhibits the cortisol hypersecretion of depressed subjects and 
that their response differs from the response of normals in that there is no acute initial 
release. Both the inhibitory and excitatory effects of norepinephrine of the secretion of 
ACTH and cortisol have been implicated in explaining these results. Thus, the disinhibited 
cortisol secretion in depression is considered to be the result of decreased tonic inhibition 
due to decreased noradrenergic activity., This noradrenergic deficit is presumably reversed 
by dextroamphetamine which via release of norepinephrine Inhibits cortisol secretion. 
Alternatively it has been suggested that subsensitivity of postsynaptic a-adrenergicreceptors 
(presumably excitatory) is responsible for the disinhibited HPA axis activity and the attenu- 
ated cortisol response to methamphetamine and dextroamphetamine. It is evident that improved 
understanding of the precise role of norepinephrine in the regulation of the human HPA axis 
is necessary before any firm conclusions can be drawn regarding the role of norepinephrine in 
this neuroendocrine abnormal i’ty, 
Serotonin. The serotonin antagonist, cyproheptadine, has been shown to suppress the ACTH- 
cortisol disinhibition in Cushinn’s disease (Krieger et al,. 1975). Evidence. however. 
regarding the role of serotonin in the disinhibrted HPA axis activity in depression is scanty., 
Carroll and co-workers (1380) reported a positive correlation between cerebrospinal fluid 
levels of the serotonin metaBolite 5vHlAA and postydexamethasone plasma cortisol levels in 
patients with endogenous depressPon. Others (Asberg et al,, 1981) were unable to replicate 
this finding but di,d report a positive correlation between cerebrospinal fluid cortisol and 
5-HIAA (Traskman et al., 1580). The latter, however, could be accounted for by the canmon 
correlation of both variables with body height. It is important at this point to emphasize 
that the classical biogenic amine hypothesis implicates a serotonin deficit in the patho- 
physiology of depression and that a positive correlation between measures of disinhibition of 
the HPA axis and increased serotonin turnover may be hard to reconcile with this hypothesis. 
Clearly, more studies are needed before any conclusion can be drawn regarding the role of 
serotonin in this neuroendocrine abnormali’ty. 
Acetylcholine. In contrast to the indirect evidence in support of the role of norepineph- 
rine and serotonin in this neuroendocrine abnormality, the role of cholinergic transmission 
in the cortisol escape fro-n dexamethasone suppression has been studied directly by Carroll 
and co-workers (1980). Dexamethasone was given orally at 2300 hours to produce suppression 
of plasma cortisol levels to healthy volunteers. The next day the actylcholinesterase 
inhibitor, physostigmine, was administered intravenously. Before the physostigmine began the 
subjects received methylscopolamine to block the peripheral effects of physostigmine. Control 
experiments were performed in which the stressful side effects of physostigmine were induced 
by oral ipecacuanha. Dexamethasone, as expected, induced persistent suppression of plasma 
cortisol. A clear rise in plasma cortisol was induced by physostigmine. Thus, normal 
subjects manifested an escape from dexamethasone suppresslon associated with the administra- 
tion of the acetylchollnesterase inhibitor physostigmlne. Atropine, but not scopolamine, 
glven before physostigmine prevented the escape. Cortisol levels did not increase in 
association with nausea induced by ipecacuanha. These results indicate that HPA escape from 
dexamethasone can be induced in normals by a muscarinic cholinergic mechanism and advocate an 
important role for actylcholine in the pathophysiology of the disinibited HPA axis activity 
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in depression. 
B. Possible Role of an impaired Opioid Inhibitory Mechanism 
There is considerable evidence in the experimental animal that the pituitary B-endorphin 
and ACTH-cortisol systems are anatomically and functionally related (&illemin et al.,.1977; 
Bloom et al.. 1977: Mains et al.. 1977: Vale et al.. 1981?. 
c&l lnlai localization-and sicretory regulation, 
In addition to sharinq a carmon 
precursor, they have a ccmnon clyc&orticoid 
feedback mechanism since dexamethasone inhibits the secretion of both peptides (Gui llemin et 
al., 19771. In man, the administration of dexamethasone suppresses ACTH and cortisol (Liddle 
et al., 1962; Berson and Yaiow, 1968) while recent evidence suggests that it also suppresses 
B-endorphin (Mathews et al., 1982) _ Conversely there is evidence that opioids regulate the 
HPA axis since naloxone, an opioid antagonist, increases ACTH and cortisol (Volavka et al., 
1979; floriey et al., 1979; Grossman et al., 1982). In the series of studies described below 
we have used a morphine infusion paradigm to provide evidence for an opioid inhibitory mecha- 
nism on the human ACTH-cortisol system. In addition, our results suggest that this mechanism 
is impaired in pati~ents with endogenous depression. 
Subjects and Methods. We have studied informed psychiatric inpatients (n=32) and healthy 
volunteers (n-4) of either sex. All pati,ents wepe drug-free for at least one week prior to 
the study. After an overnight fast, subjects remained supi’ne from 7:30 a.m. until the 
completion of the study An indwelling catheter was i’nserted in the antecubital vein at 
8:30 a.m. and kept open with a slow infusion of heparinized normal saline. Morphine sulfate, 
5 mg, was injected intravenously at 9:30 a.m., Blood samples were drawn 15, immediately 
before, 30, 60, 90, 120, and 180 minutes after the morphine injection. In six of the patient’s 
and in the four healthy volunteers, the effect of morphine was canpared to a placebo injec- 
tion (normal saline) 24 hours before or 48 hours after the morphi;ie procedure. A Dexanetha- 
sane Suppression Test administered 48 to 96 hours after the morphine procedure was performed 
as standardized by Carroll (1980). A plasma cortisol concentration greater than 5 pg/dl at 
4:OO p.m. or 11:OO p.m. was considered abnormal (positive). Total plasma corticoids 
(“cortisol”) were measured by the transcortin method of Murphy (1967). Diagnoses were made 
according to the Research Diagnostic Criteria (Spitzer et al., 1975) on the basis of all 
clinical information and a structured interview (Endicott and Spitzer, 19781, Diagnoses 
were made without access to the morphine infusion or the Dexamettiasone Suppression Test 
results. 
Results. Morphine suppressed cortisol secretion in all healthy volunteers. Figure I 
illustrates the effect of morphine on plasma cortisol in a healthy male volunteer. 
Figure 1. Effect of morphine (5 mg) on plasma 
cortisol in a healthy volunteer 
Cortisol levels decline progressively for the duration of the experiment after the morph1 ne 
injection. in contrast, there is evidence for continuous secretory activity following the 
administration of placebo. Figure II illustrates the effect of morphine on platia cortisol 
in a female patient with a diagnosis of major depressive disorder, endogenous subtype. 








Figure 2. Effect of morphine (5 mg) on plasma 
cortisoi in a patient with major 
depression, endogenous subtype. 
Baseline cortisoi levels are, as anticipated, higher than those in the normal volunteer and 
remain high after the administration of placebo. In sharp contrast, they decline progres- 
sively for the duration of the experiment in response to the morphine injection. This 
progressive decline, at a rate consistent with the half life of cortisoi (Peterson and Wyn- 
gaarden, 1956). has been observed in ail healthy volunteers and psychiatric inpatients studied 
with the exception of approximately thirty percent of patients with major depressive disorder 
or schizoaffective disorder, depressed. In these patients, after the initial suppression of 
cortisoi secretion there is an unambiguous upward swing of cortisoi values indicating early 
resumption of corti sol secret ion (escape). 
The effect of morphine on cortisol secretion in one of these patients before and after a 
successful course of eiectroconvulsive treatment is depicted in Figure III. 
M) 0 1.0 
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Figure 3. Effect of morphine (5 mg) on plasma 
cortisoi in a patient with major 
depression, endogenous subtype 
before and after treatment. 
Before treatment, plasma cortisoi levels started to rise at the 120 and 180 minutes blood 
samples indicating resumption of cortisoi secretion whereas following treatment, when the 
patient was no longer depressed, cortisoi values declined progressively for the duration of 
the experiment. Thus, it appears that this abnormality, i.e. early escape of cortisoi from 
morphine suppression, is state dependent. 
Dexamethasone suppression and the opiates 567 
We cunpared Dexamethasone Suppression Test results with the effect of morphine on plasma 
cortisol for the patients with major depression, endogenous subtype. We found an association 
between abnormal Dewamethasone Suppression Test results and early resumption of cortisol 
secretion following morphine administration. Within this diagnostic category cortisol escape 
from morphine suppression was 1 imited to patients with abnormal Dexamethasone Suppression 
Test results. 
Conclusions. The data presented here are consistent with the presence of an inhibitory 
opioid mechanism in the human HPA axis. Perhaps more important is the observation that the 
HPA axis appears to be insufficiently inhibited by this opioid mechanism in patients with 
major depression compared to normals or patients with other psychiatric diagnoses. Thus, the 
disinhibited activity of the HPA axis in patients with depression is resistant to both opioid 
(morphine) inhibition and glucocorticoid (dexamethasone) feedback. These observations 
suggest that the pathophysiology of this neuroendocrine disturbance is not limited to classi- 
cal neurotransmitter-HPA axis interactions but that it also involves inhibitory opioid 
mechanisms. 
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